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Abstract
CD4+CD25+FOXP3+ regulatory T cells (Treg) require activation through the T cell receptor for function.
CD4+CD25+FOXP3+ regulatory T cells are believed to be key players of the immune tolerance network and 
control the induction and effector phase of the immune system. Although these cells require antigen-specific 
activation, they are generally able to suppress bystander T cell responses once activated. This raises the possibility 
that antigen-specific Treg may be useful therapeutically by localizing generalized suppressive activity to tissues 
expressing select target antigens. Treg can exert a potent suppressive effect on immune effector cells reactive to 
host antigens and prevent graft versus host disease (GVHD) in allogeneic bone marrow transplantation (BMT). 
Here, we observed that co-transfer of CD4+CD25+FOXP3+ T cells derived from donor type along with the 
donor bone marrow cells could control GVHD-like reactions by suppressing effectors cells of  host responding 
to the donor hematopoietic compartment, and resulted in prevention of autoimmunity and rejection. We further 
demonstrate that CD4+CD25+FOXP3+ regulatory T cells can control immune-based morbidity after allogeneic 
BMT by suppressing the development of granulocytes cells and increasing the level of  B cell expression.
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Introduction 
Graft-versus-host disease (GVHD 
continues to be a major life-threatening 
complication after allogeneic bone marrow 
transplantation. Some effort has been made to 
elucidate the patho-physiology of acute GVHD. 
Antigenic differences on antigen-presenting cells 
(APC) of the host was directly recognized by 
mature donor T cells transferred along with the 
marrow and donor antihost-specific T cells can 
mediate tissue destruction. Even though GVHD 
in allogeneic system always occurs until now we 
have no choice because for some disease highly 
dependent on bone marrow transplantation 
(BMT). BMT  is the only curative treatment for 
myelofibrosis, and again allergy also a factor 
need more attention because evolved in final 
results. The risk for severe acute GVHD was 
increased after allo-SCT from mismatched 
donors. However, disease status at 
transplantation is the most important prognostic 
factor for transplantation success (1-6). The 
failure of clonally deleted of autoreactive T cells 
in the thymus is one of the reasons to initiate an 
autoimmune diseases and some symptoms look 
like GVHD. Clonal deletion in the thymus may 
be impaired  either by damage to the thymic 
epithelium or by the use of immunosuppressive 
drugs that inhibit clonal deletion. Mature donor 
T cells transferred along with the marrow graft 
directly recognize antigenic differences on 
antigen-presenting cells  of the host. Once 
activated, donor T cells that specifically respond 
to the host compartment can   mediate   tissue 
destruction (6-10). Induction of immunological 
tolerance to alloantigens would be the treatment 
of choice to  prevent graft-versus-host disease 
(GVHD) and allograft rejection in 
transplantation medicine. The most potent self-
tolerance mechanism is probably dominant 
tolerance assured by regulatory and suppressor T 
lymphocytes. The potential utilization of Treg in 
preventing GVHD has been studied in several 
animal models. In some studies, purified 
populations of CD4+CD25+ cells from 
syngeneic mice infused together with the graft 
successfully prevented the development of 
GVHD. This strategy is based on the notion 
that the Treg suppressive activity is best exploited 
when the anti-host response has not fully 
developed. In contrast, other studies 
demonstrated the capacity of Treg cells infused 
later after transplant to control already 
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established GVHD. These latter findings 
support the view that Treg could also be utilized 
to correct chronic GVHD in humans. 
Interestingly, most studies report that Treg
expanded in vitro with IL-2 exhibit higher 
suppressive capabilities than freshly isolated Treg. 
These data provides additional support for the 
use of in vitro expanded Treg as a source for 
cellular immunotherapy. Treg exert their 
suppressive function over a wide range of T cells 
including tumor specific effector T lymphocytes. 
It is therefore likely that the infusion of Treg at 
the time of BMT would decrease the beneficial 
GVL effect promoted by donor T cells. 
Regulatory T cell may be one of the component 
to inhibit GVH-like reaction or autoimmune 
disorder. Multiple populations of cells is now 
claimed to participate in this process. However, 
CD4+ regulatory T cells that innately express 
CD25+ appear to be of the best component to 
control the immune response. Evidence for 
regulatory T cells in clinical bone marrow 
transplantation, however, remains unclear. The 
finding of CD4+CD25+ regulatory T cells that 
preferentially express the Foxp3 nuclear 
transcription factor and the development of 
molecular reagents to isolate antigen-specific T
cells have provided unique opportunities to 
explore immunoregulatory mechanisms after 
clinical marrow trans-plantation. In recent 
studies we test the efficacy of 
CD4+CD25+FOXP3+ cells whether they play a 
vital role in the regulatory control of GVH 
reactions mediated by both alloreactive and 
autoreactive lymphocytes. Immune reaction 
against virulent foreign objects could be harmful 
for self-organism. Therefore, a strict regulatory 
mechanism must exist in the immune system 
(11-16). CD4+CD25+ is now well documented as 
the key that control immune activity. However, 
other cells, especially those of CD8+ T cell 
lineage, have also been suggested as regulatory T 
cells ( 17, 18). In previous study we have tested 
the capacity of CD8+CD122+ regulatory T cells 
to rescue an autoimmune disorder in IL-2Rβ-/-
(CD122 knockout) mice. CD122 knockout 
exhibits severe autoimmune disorder 
characterized by increasing of activated T cells. 
The mice are also safer from severe anemia 
because of erythropoiesis suppression. Usually 
severe anemia progresses and the mice die in the 
ages of 3-4 months. We found that expansion of 
abnormally activated T cells is the underlying 
cause of all phenotypes (24). The mechanism of 
generation of activated memory-type T cells in 
CD122-deficient mice is controversial. In the 
initial investigations by Abbas and others (17-19), 
the defect of programmed cell death (apoptosis) 
in IL-2 or IL-2Rβ-deficient T cells could be 
applied to the mechanism for survival of 
activated CD122-deficient T cells, and such 
possibility has not been excluded. Because  IL-
2R molecule appear to include in vast major 
array in homeostasis system, we highlight 
CD25+ (IL-2Rα) to investigate the function in 
allogeneic transplantation. We hypothesize   that 
the lack of certain regulatory cells was 
responsible for the induction of both 
hematopoietic disorder and autoimmune 
diseases. In this study, however, direct evidence 
of the responsible subpopulation in CD4+ cells 
was not provided, and it was still unclear 
whether the lack of regulatory system is 
sufficient to cause GVH-like reaction in 
allogeneic bone marrow transplantation. Here, 
we report a novel observation that transfer of 
highly purified CD4+CD25+FOXP3+T cells 
from donor type adapted in F1 mice along with 
marrow graft in the allogeneic sytem of 
(C57BL/6 to BALB/c) resulted in normalization 
the ratio of Gr1 cell / B cell, inhibition of 
memory type development, and finally bone 
marrow recipient remain healthy two month 
post BMT. This result indicates that 
CD4+CD25+FOXP3+ T cell population contains 
novel regulatory T cells that effectively control 
GVH-like reaction in allogeneic BMT with 
mismatch-MHC and also potent suppressive 
effect on immune effector cells reactive to host 
antigens and prevent graft versus host disease 
(GVHD).
MATERIAL AND METHOD
A. Mice
Breeding pairs of C57BL/6CD45.1/CD45.1
congenic strain were maintained in our animal 
facility. BALB/c (H-2d) and CBF1 were use as  
host and T cells adaptation, respectively. Donor 
cells were obtained from C57BL/6 mice.
B. Antibodies
Biotin-conjugated anti-mouse  FOXP3 
(clone FJK-16s), phycoerythrin (PE)-conjugated 
anti-mouse B220 (clone RA3-6B2), Fluorescein 
isothiocyanate (FITC)-conjugated anti-mouse 
CD8a (clone53-6.7), phycoerythrin (PE)- or 
allophycocyanin (APCn)-conjugated anti-mouse 
CD4 (clone GK1.5), biotin-conjugated anti-
mouse, FITC-conjugated anti-mouse CD25 
(clone PC61.5), FITC- or biotin-conjugated 
anti-mouse CD45.1 (clone A20), and biotin-
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conjugated anti-mouse TER-119 (clone TER-
119) antibodies were purchased from 
eBioscience Inc. (San Diego, CA). FITC-
conjugated anti-mouse CD69 (clone H1.2F3), 
FITC-conjugated anti-mouse CD44 (clone IM7), 
PE-conjugated anti-mouse CD62L (clone MEL-
14), FITC-conjugated anti-mouse Gr-1 (clone 
RB6-8C5) antibodies were purchased from BD-
Biosciences Pharmingen (San Diego, CA). 
Biotin-conjugated antibodies were visualized by 
streptavidin-PE-Cy5 (eBioscience, San Diego, 
CA). CD45.1 is antibody to distinguish donor 
derived cells from recipient derived cells.
C. Flow cytometry and cell sorting
Analytical flow cytometry was performed 
using FACS CaliburTM flow cytometer (BD-
Biosciences, San Jose, CA). Preparative cell 
sorting was performed using FACS Vantage cell 
sorter (BD-Biosciences, San Jose, CA).
D. Bone marrow transfer
Bone marrow transfer was done after 
recipient mice treated with lethal dose radiation 
of 850 RAD. Bone marrow cells (1~2 x 106) 
from C57BL/6 were intravenously injected to 
BALB/c recipient mice. 
E. Intracellular cytokine staining
Intracellular cytokine staining was performed 
using a Cytofix/Cytoperm kit (BD-Biosciences 
Pharmingen) according to the protocol 
provided by the manufacturer. Cells were 
incubated with biotin-conjugated anti-FOXP3 
antibody and visualized with streptavidin-PE-
Cy5.
RESULT AND DISCUSSION 
CD4+CD25+FOXP3+ cells prevent expansion  
activated T cells in recipient of BMT. In allogeneic 
bone marrow transplantation lethal dose 
radiation is needed to prevent immune attack 
specially from recipient immune system. Lethal 
dose radiation also provide a space in which 
donor cells have a big chance to develop with 
lower competition. Figure 1 showed that 850 
RAD served as one factor in order donor cell 
can be accepted by recipient. Figure 1 showed 
that the donor cell can reconstitute recipient cell 
more than 90%. As shown in Figure 2 and 
Figure 3, transfer of bone marrow alone or in 
combination  CD4+CD25-FOXP3-  had high 
percentage of activated memory-type T cells 
with markers of CD69+and CD62L-. In contrast, 
recipient mice that received 
CD4+CD25+FOXP3+ 2x105 cells showed no 
such increase of activated CD69+ T cells (Figure
2 ) and CD62L- activated memory-type T cells 
(Figure 3). Transfer of CD4+CD25-FOXP3- T 
cells into recipient did not prevent the 
development of activated CD69+ T cells  and 
CD62L- memory-type T cells. These results 
indicate that at least 2x105
CD4+CD25+FOXP3+  cells are sufficient to 
perform regulatory activity when transferred 
together with graft bone marrow. We analyzed 
both CD4+ T and CD8+ T cells to know the 
status of activated T cells.
Figure 1. CD4+CD25+ regulatory T cells emerged from both donor 
and radiation resistance cells. After 8 wk post bone 
marrow transplantation, spleen cells obtained from 
recipient (host) mice were stained with anti-CD25, anti-
CD4, and anti-CD45.1 antibodies, and analyzed by flow 
cytometry. Expression levels of CD25 are shown as dot 
plot for cells derived from both donor (CD45.1+) and 
recipient (CD45.1-). This pictures show that lethal dose 
radiation increase hematopoietic reconstitution in 
allogeneic system and most hematopoietic cells emerged 
from donor type. Data are mean  SD values of three 
mice.
Figure 2. CD4+CD25+FOXP3+ Treg inhibites T cell activation in 
vivo. T cell-depleted bone marrow cells obtained from 
C57BL/6 mice (2x 106) were intravenously injected into 
irradiated (8.5 Gy)BALB/c mice. BM cells alone or those 
in combination with CD4+CD25+FOXP3+ or 
CD4+CD25-FOXP3- cells (2 x 105) were injected as 
indicated in the figure. Two months post BMT, spleen 
cells were analyzed by flow cytometry to assess the CD69 
T cells. The result showed that the percentages of CD69+
in CD8+ population decrease in spleen of mice that 
received allogeneic BM cells together with 
CD4+CD25+FOXP3+ Treg.
CD4+CD25+FOXP3+ cells normalize 
granulocytes, B cells, and erythrocytes in recipient mice. 
Examination of granulopoiesis showed that the 
number of Gr-1+ cells in the bone marrow was 
markedly increased in recipient accepted BM 
alone or in combination with CD4+CD25-
FOXP3- T cells (Figure 4). This increase was 
normalized by transferring 2x105
CD4+CD25+FOXP3+ cells into recipient but 
not by transferring 2x105 CD4+CD25-FOXP3-  
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cells  T cells (Figure 4). Changes in the number 
of Gr-1+ cells in the bone marrow matched 
those of leukocyte numbers in peripheral blood 
(data not shown). Increased leukocyte number 
in peripheral blood of recipient mice was 
normalized by the transfer of 2x105
CD4+CD25+FOXP3+ cells into recipient but 
neither by the transfer of BM alone nor by that 
of 2x105 CD4+CD25-FOXP3-. Hair lost and 
skin injure caused by a combination of 
autoimmune hemolysis and suppression of 
erythropoiesis is another striking feature of 
BMT without manipulation using Treg. 
Examination of erythroid-lineage cells by 
expression of TER-119 antigen, an erythroid 
specific marker, showed marked reduction in 
the number of TER-119+ cells in the bone 
marrow of recipient BMT lacking of regulatory 
T cells. This erythroid suppression was also 
rescued by the transfer of 2x105
CD4+CD25+FOXP3+  cells into recipient, 
whereas the transfer of 2x105 CD4+CD25-
FOXP3- cells was ineffective, resulting in the 
same decrease of TER-119+ cells as that in 
transfer of BM alone (Figure 5). 
Figure 3. T cell-depleted bone marrow cells obtained from 
C57BL/6 mice (2 x 106) were intravenously injected 
into irradiated (8.5 Gy)BALB/c mice. BM cells alone 
or those in combination with CD4+CD25+FOXP3+ or 
CD4+CD25-FOXP3- cells (2 x 105) were injected as 
indicated in the figure. Two months post BMT, spleen 
cells were analyzed by flow cytometry to assess the 
CD62L T cells. The result showed that CD62L+ T cells 
increase in mice that received allogeneic BM cells 
together with CD4+CD25+FOXP3+ Treg.
It is now well documented from 
experimental in animal model that Tregs
represent a potential new therapeutic modality
for the control of GVHD. Unfortunately Treg
remain anergy by TCR mediated stimulation. In 
individual, the frequency of Treg is very low in 
the T cell compartment.  To achieve a clinical 
benefit in the setting of murine GVHD, a phase 
of ex vivo expansion of Treg would probably be 
mandatory. This  approach may also be effective 
in humans. After confirming the preventive 
effects of CD4+CD25+FOXP3+ we 
recommended to combine both CD4 and CD8 
derived Treg in allogeneic BMT.  
Figure 4. CD4+CD25+FOXP3+ Treg maintain normal ratio of B 
cells and granulocyte cells. T cell-depleted bone marrow 
cells obtained from C57BL/6 mice (2 x 106) were 
intravenously injected into irradiated (8.5 Gy)BALB/c 
mice. BM cells alone or those in combination with 
CD4+CD25+FOXP3+ or CD4+CD25-FOXP3- cells (2 x 
105) were injected as indicated in the figure. Two months 
post BMT spleen cells were analyzed by flow cytometry 
to assess the B cell / Granulocyte ratio. The result 
showed normalization of B cell / Granulocyte ratio in 
mice that received allogeneic BM cells together with 
CD4+CD25+FOXP3+ cells.
Figure 5. Increased erythropoiesis and reduced granulopoiesis in 
recipient mice that received CD4+CD25+FOXP3+.. Bone 
marrow cells obtained from mice that had received 
allogeneic BMT in combination with      
CD4+CD25+FOXP3+ or CD4+CD25- FOXP3- cells were 
stained with anti-Gr-1 and anti-TER-119 antibodies. 
Percentages of cells in myeloid lineage (Gr-1+TER-119-) 
and cells in erythroid lineage (Gr-1-TER-119+) are shown.
In a model of GVHD prevention using 
freshly purified Tregs, Edinger et al. (22) showed 
a strong inhibition of expansion of donor T cells. 
However, in a cell-per-cell analysis of donor T 
cells, the addition of freshly purified Tregs had 
minimal or no effect on the acquisition of 
activation markers and IFN- production. Here 
we observed  that CD4+CD25+FOXP3+ Tregs
strongly inhibited the division and expansion of 
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host remaining T cells. It is clear that 
CD4+CD25+FOXP3+ Tregs promote the donor 
engraftment and replaced host derived T cells 
(Figure7). CD4+CD25+ FOXP3+ expanded Tregs
additionally inhibit the development of donor 
toward Gr1 cells (Figure3). The function of 
CD4+CD25+FOXP3+ Treg could be mediated by 
IL-10 and TGFβ production. In the system of 
in vitro, CD4+CD25+FOXP3+ can suppress T 
cells proliferation under anti-CD3 stimulation 
and in the presence of antigen-presenting cell 
(APC) (Figure5). This property of Tregs could 
explain why expanded Tregs seem to have a more 
profound suppressive effect on the activation of 
donor T cells in an allogeneic BMT setting. 
Here we propose that GVHD is not due to the 
early expansion and differentiation of 
alloreactive donor T cells. In this case we have 
an evident that absolute exclusion of mature 
donor T cells from donor marrow could not 
inhibit such activation, this explains that may be 
Treg is one component necessary to prevent the 
disease. It had been demonstrated that 
CD4+CD25+ Tregs efficiently prevent GVHD 
(17, 18). Other group demonstrated that 
CD4+CD25+ can ameliorate GVHD.
Figure 6. CD4+CD25- T cells cocultured with 
CD4+CD25+FOXP3+ Treg become unresponsive to 
anti-CD3 stimulation. Purified CD4+CD25- T cells 
were cultured either alone or cocultured with 
CD4+CD25+FOXP3+ Treg at ratio 2:1. Cultures were 
performed in 96-well round bottom plates in the 
presence of T cell-depleted and gamma irradiated 
(3000Rad) spleen cells as an APC source and soluble 
anti-CD3. Incubation was performed 72 hrs in a 
medium containing rIL-2 (50 ng ml-1). After culture, 
cells were harvested and analyzed using standard 
method of 3H- Thymidine uptakes. Proliferation rate 
of T cells is presented in the panels. 
The better effect of Tregs could rely on their 
increased ability to rapidly become activated in 
vivo, and exert their immunosuppressive effect 
early after infusion. In further support of this 
concept, it was recently showed that in fully 
MHC-mismatch, GVHD usually occur when 
Tregs from adoptive transfer are rejected (20).
Early after injection, most of Treg are likely 
activated by their cognate allogeneic Ags in the 
system of syngeneic BMT, but will be rejected 
in fully MHC-mismatch. Another point is that 
Tregs also could display a suppressive effect 
mainly targeted to alloreactive donor T cells, 
whereas non-alloreactive donor T cells could be 
partially spared. Here, we show that 
CD4+CD25+FOXP3+ Tregs were not rejected by 
recipient and have a capacity to prevent both 
donor and host type T-cells from developing 
become activated memory type (Figure 2, 3). 
This data suggest that Tregs contribute to 
silencing T cell reactivity between donor and 
host. In a previous report, we showed the 
function of Treg to ameliorate autoimmune 
destruction in syngeneic model experiment (21). 
Figure 7. CD4+CD25+FOXP3+ Treg promote host remaining T cell 
replacement. T cell-depleted bone marrow cells obtained 
from C57BL/6 mice (2 x 106) were intravenously injected 
into irradiated (8.5 Gy)BALB/c mice. BM cells alone or 
those in combination with CD4+CD25+FOXP3+ or 
CD4+CD25-FOXP3- were injected as indicated in the 
figure. Two months after BMT, spleen cells were 
analyzed by flow cytometry to assess T cell replacement. 
The result indicated that CD4+CD25+FOXP3+ T cells 
promoted T cell replacement from host type to donor 
type.
After Treg cell transfer in lymphopenic
recipients, we observed that activated T cells are 
down-regulated. This down-regulation looks 
very similar with Treg cells transfer in allogeneic 
system. Treg cells could suppress early activated 
T cells and inhibit CD69 expression then keep 
the existence of CD62L on cell surface (Figure 2, 
3). In contrast, in the absent of Treg the mice 
model of autoimmune disease will die because 
of activated T cell reaction. Alloreactive and 
nonalloreactive T cells can be discriminated by 
the expression of CD62L and also CD69 (22-
24). In this study, we observed that T cells that 
express CD62L in the presence of Tregs behaved 
as nonalloreactive T cells. Indeed, Tregs
dramatically reduced the expansion and 
differentiation of host remaining T cells, and
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most of the remaining dividing host T cells 
expressed CD69 and loss the CD62L.This 
suggests that, when using CD4+CD25+ FOXP3+,
activation and differentiation of alloreactive T 
cells in effector T cells involved in GVHD are 
inhibited by these Tregs whereas nonalloreactive
T cells can expand. In allogeneic BMT, GVHD 
may contribute to the destruction of lymphoid 
organ. In this report we observe that GVHD 
also related to donor rejection and remaining 
host T cell development. Because we observed a 
better immune reconstitution when Tregs were 
used, it is likely that, in this situation,
nonalloreactive donor T cells expand 
significantly in the recipient and participate to 
the improved immune reconstitution and T cell 
replacement from recipient increased.
The use of Tregs for the control of GVHD 
in allogeneic BMT is an area of debate of intense 
interest. However, to date, nothing is known 
regarding the respective therapeutic benefit of 
the most effective Tregs in humans. In a clinical 
setting, the primary difference between 
CD4+CD25+ and CD8+CD28- has not been 
tested yet. We hypothesize that combination of 
both CD4 and CD8 Treg may effectively protect 
the body weigh loss in allogeneic BMT. These 
Tregs seem to be more complicated without 
knowing the molecules which is recognized in 
the regulatory of action. The generation of Tregs
would probably raise more technological issues 
because of the necessity to use APCs, as 
opposed to clinically standardized beads. The 
necessity to select nonmalignant APCs when 
BMT is performed for the treatment of 
leukemia could be an additional major hurdle. 
Furthermore, the duration of the culture to 
achieve clinically relevant cell numbers could be
longer with Tregs. Indeed, in mice, to obtain high
numbers of Tregs, take over 28 days. In this study, 
we used equivalent numbers of Tregs and 
suspected non Tregs (CD4+CD25-FOXP3-) and 
observed that Tregs are more efficient than non 
Tregs in controlling GVHD. It is quite possible 
that infusion of higher numbers of Tregs promote 
better of GVHD inhibition and promotion of 
immune reconstitution. In fact, some studies  
(26) demonstrated that by increasing the number 
Treg 3-fold (three Tregs per infused allogeneic T 
cell), nearly complete inhibition of overt GVHD 
was durably achieved despite the presence of 
histopathological signs of GVHD in target 
organs. Again our study empesis that Treg
function not only inhibit alloreactive T cells but 
also promote donor engraftment. However, to 
be clarified, this point deserves specific 
experiments, such as comparing the effect of 
Tregs in very small number of BM cells and huge 
number of BM cells in allogeneic BMT system. 
Our work demonstrates that 
CD4+CD25+FOXP3+ Tregs are  efficient in 
providing durable protection from GVHD and 
facilitate immune reconstitution after allogeneic 
bone marrow transplantation. Since only donor 
derived CD4+CD25+FOXP3+ Treg could be 
effective in allogeneic BMT,  thus, we propose 
that Tregs should be explored and adapted again 
host as a viable modality for treating human 
GVHD in the setting of allogeneic bone marrow  
transplantation. Because so far there are no 
preclinical data have demonstrated in human to 
maintain the GVHDL effect (21, 27-30), this 
still remains to be studied in clinical trials. 
CONCLUSION
CD4+CD25+FOXP3+ Treg cells contribute 
to inhibit GVH-like reaction. It is important to 
find a strategy to isolate and expand 
CD4+CD25+FOXP3+ regulatory T cells. 
CD4+CD25+FOXP3+ Tregs actively inhibit the 
development of GVH-like reaction by 
increasing graft engraftment and preventing T 
cell activation. Emerging data provide a new 
evident to change old paradigm that GVHD is 
problem of mature T cell contamination from 
donor type. Here, we postulate that GVHD is 
not problem of mature T cell contamination 
from donor type but rather of lacking or non 
functional of Treg. Finally we recommend  to 
combine CD4+CD25+FOXP3+ Treg with 
CD8+CD28- Treg in allogeneic bone marrow  
transplantation.
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